Moderna

Moderna has begun a Phase 1 clinical trial of an Ebola vaccine targeting the Zaire strain responsible for the outbreak in the Democratic Republic of the Congo. The trial marks the first human testing of the candidate, which uses the same mRNA technology behind Moderna's COVID-19 vaccine. Coverage is highlighting the company's growing pipeline and the urgent need for new Ebola countermeasures in central Africa.

The updated 2026-2027 COVID-19 vaccine is now available in the United States, with people booking annual booster appointments at pharmacies such as Walgreens, including for the Moderna shot. The rollout comes amid reports of a 13th COVID wave, with outbreaks in 40 states and territories and millions of cases cited in a September 2026 update from pandemic data tracker Michael Hoerger.